IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v1y2017i1d10.1007_s41669-016-0009-9.html
   My bibliography  Save this article

The Potential Cost-Effectiveness of HIV Vaccines: A Systematic Review

Author

Listed:
  • Blythe Adamson

    (Department of Pharmacy, University of Washington)

  • Dobromir Dimitrov

    (Fred Hutchinson Cancer Research Center)

  • Beth Devine

    (Department of Pharmacy, University of Washington)

  • Ruanne Barnabas

    (Fred Hutchinson Cancer Research Center
    University of Washington)

Abstract

Objective The aim of this paper was to review and compare HIV vaccine cost-effectiveness analyses and describe the effects of uncertainty in model, methodology, and parameterization. Methods We systematically searched MEDLINE (1985 through May 2016), EMBASE, the Tufts Cost-Effectiveness Analysis (CEA) Registry, and the reference lists of articles following Cochrane and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Eligibility criteria included peer-reviewed manuscripts with economic models estimating the cost-effectiveness of preventive HIV vaccines. Two reviewers independently assessed study quality and extracted data on model assumptions, characteristics, input parameters, and outcomes. Results The search yielded 71 studies, 11 of which met the inclusion criteria. Populations included low-income (n = 7), middle-income (n = 4), and high-income countries (n = 2). Model structure varied, including decision tree (n = 1), Markov (n = 5), compartmental (n = 4), and microsimulation (n = 1). Most studies measured outcomes in quality-adjusted life-years (QALYs) gained (n = 6), whereas others used unadjusted (n = 3) or disability-adjusted life-years (n = 2). The range of HIV vaccine costs were $US1.54–75 in low-income countries, $US55–100 in middle-income countries, and $US500–1000 in the USA. Base-case incremental cost-effectiveness ratios (ICERs) ranged from dominant (cost offsetting) to $US91,000 per QALY gained. Conclusion Most models predicted HIV vaccines would be cost-effective. Model assumptions about vaccine price, HIV treatment costs, epidemic context, and willingness to pay influenced results more consistently than did assumptions on HIV transmission dynamics.

Suggested Citation

  • Blythe Adamson & Dobromir Dimitrov & Beth Devine & Ruanne Barnabas, 2017. "The Potential Cost-Effectiveness of HIV Vaccines: A Systematic Review," PharmacoEconomics - Open, Springer, vol. 1(1), pages 1-12, March.
  • Handle: RePEc:spr:pharmo:v:1:y:2017:i:1:d:10.1007_s41669-016-0009-9
    DOI: 10.1007/s41669-016-0009-9
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-016-0009-9
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1007/s41669-016-0009-9?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. David O. Meltzer & Ties Hoomans & Jeanette W. Chung & Anirban Basu, 2011. "Minimal Modeling Approaches to Value of Information Analysis for Health Research," Medical Decision Making, , vol. 31(6), pages 1-22, November.
    2. Don Husereau & Michael Drummond & Stavros Petrou & Chris Carswell & David Moher & Dan Greenberg & Federico Augustovski & Andrew Briggs & Josephine Mauskopf & Elizabeth Loder, 2013. "Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(3), pages 367-372, June.
    3. David O. Meltzer & Ties Hoomans & Jeannette W. Chung & Anirban Basu & Kathryn J. Aikin & Amie C. O’Donoghue & John L. Swasy & Helen W. Sullivan & David G. T. Whitehurst & Stirling Bryan & Martyn Lew, 2011. "Minimal Modeling Approaches to Value of Information Analysis for Health Research," Medical Decision Making, , vol. 31(6), pages 785-786, November.
    4. Briggs, Andrew & Sculpher, Mark & Claxton, Karl, 2006. "Decision Modelling for Health Economic Evaluation," OUP Catalogue, Oxford University Press, number 9780198526629.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Christian Selinger & Dobromir T. Dimitrov & Philip A. Welkhoff & Anna Bershteyn, 2019. "The future of a partially effective HIV vaccine: assessing limitations at the population level," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 64(6), pages 957-964, July.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Haitham Tuffaha & Claire Rothery & Natalia Kunst & Chris Jackson & Mark Strong & Stephen Birch, 2021. "A Review of Web-Based Tools for Value-of-Information Analysis," Applied Health Economics and Health Policy, Springer, vol. 19(5), pages 645-651, September.
    2. David Glynn & Vijay S. Gc & Karl Claxton & Chris Littlewood & Claire Rothery, 2024. "Rapid Assessment of the Need for Evidence: Applying the Principles of Value of Information to Research Prioritisation," PharmacoEconomics, Springer, vol. 42(9), pages 919-928, September.
    3. Qi Cao & Erik Buskens & Hans L. Hillege & Tiny Jaarsma & Maarten Postma & Douwe Postmus, 2019. "Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 475-482, April.
    4. Neily Zakiyah & Antoinette D I van Asselt & Frank Roijmans & Maarten J Postma, 2016. "Economic Evaluation of Family Planning Interventions in Low and Middle Income Countries; A Systematic Review," PLOS ONE, Public Library of Science, vol. 11(12), pages 1-19, December.
    5. Paul Tappenden & James Chilcott, 2014. "Avoiding and Identifying Errors and Other Threats to the Credibility of Health Economic Models," PharmacoEconomics, Springer, vol. 32(10), pages 967-979, October.
    6. Maximilian Hatz & Reiner Leidl & Nichola Yates & Björn Stollenwerk, 2014. "A Systematic Review of the Quality of Economic Models Comparing Thrombosis Inhibitors in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention," PharmacoEconomics, Springer, vol. 32(4), pages 377-393, April.
    7. Manal H. El-Hamamsy & Gihan H. Elsisi & Randa Eldessouki & Mohamed M. Elmazar & Ahmed S. Taha & Basma F. Awad & Hossam Elmansy, 2016. "Economic Evaluation of the Combined Use of Warfarin and Low-dose Aspirin Versus Warfarin Alone in Mechanical Valve Prostheses," Applied Health Economics and Health Policy, Springer, vol. 14(4), pages 431-440, August.
    8. David Brain & Ruth Tulleners & Xing Lee & Qinglu Cheng & Nicholas Graves & Rosana Pacella, 2019. "Cost-effectiveness analysis of an innovative model of care for chronic wounds patients," PLOS ONE, Public Library of Science, vol. 14(3), pages 1-13, March.
    9. Magnus Zingmark & Ingeborg Nilsson & Fredrik Norström & Klas Göran Sahlén & Lars Lindholm, 2017. "Cost effectiveness of an intervention focused on reducing bathing disability," European Journal of Ageing, Springer, vol. 14(3), pages 233-241, September.
    10. Simone A. Huygens & Isaac Corro Ramos & Carlijn V. C. Bouten & Jolanda Kluin & Shih Ting Chiu & Gary L. Grunkemeier & Johanna J. M. Takkenberg & Maureen P. M. H. Rutten-van Mölken, 2020. "Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses in the aortic position in elderly patients," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(4), pages 557-572, June.
    11. Steffen Flessa & Dominik Dietz & Elisabete Weiderpass, 2016. "Health policy support under extreme uncertainty: the case of cervical cancer in Cambodia," EURO Journal on Decision Processes, Springer;EURO - The Association of European Operational Research Societies, vol. 4(3), pages 183-218, November.
    12. Ben Kearns & Roberta Ara & Allan Wailoo & Andrea Manca & Monica Alava & Keith Abrams & Mike Campbell, 2013. "Good Practice Guidelines for the use of Statistical Regression Models in Economic Evaluations," PharmacoEconomics, Springer, vol. 31(8), pages 643-652, August.
    13. Pepijn Vemer & Maureen Rutten-van Mölken, 2013. "The Road Not Taken: Transferability Issues in Multinational Trials," PharmacoEconomics, Springer, vol. 31(10), pages 863-876, October.
    14. Carmen Selva-Sevilla & Elena Conde-Montero & Manuel Gerónimo-Pardo, 2020. "Bayesian Regression Model for a Cost-Utility and Cost-Effectiveness Analysis Comparing Punch Grafting Versus Usual Care for the Treatment of Chronic Wounds," IJERPH, MDPI, vol. 17(11), pages 1-21, May.
    15. Deidda, Manuela & Geue, Claudia & Kreif, Noemi & Dundas, Ruth & McIntosh, Emma, 2019. "A framework for conducting economic evaluations alongside natural experiments," Social Science & Medicine, Elsevier, vol. 220(C), pages 353-361.
    16. Anirban Basu & David Meltzer, 2012. "Private Manufacturers’ Thresholds to Invest in Comparative Effectiveness Trials," PharmacoEconomics, Springer, vol. 30(10), pages 859-868, October.
    17. Brown, Vicki & Diomedi, Belen Zapata & Moodie, Marj & Veerman, J. Lennert & Carter, Rob, 2016. "A systematic review of economic analyses of active transport interventions that include physical activity benefits," Transport Policy, Elsevier, vol. 45(C), pages 190-208.
    18. Caroline S. Bennette & David L. Veenstra & Anirban Basu & Laurence H. Baker & Scott D. Ramsey & Josh J. Carlson, 2016. "Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group," Medical Decision Making, , vol. 36(5), pages 641-651, July.
    19. David Brain & Jonathan Mitchell & James O’Beirne, 2020. "Cost-effectiveness analysis of an outreach model of Hepatitis C Virus (HCV) assessment to facilitate HCV treatment in primary care," PLOS ONE, Public Library of Science, vol. 15(6), pages 1-13, June.
    20. Carmen Selva-Sevilla & F Dámaso Fernández-Ginés & Manuel Cortiñas-Sáenz & Manuel Gerónimo-Pardo, 2021. "Cost-effectiveness analysis of domiciliary topical sevoflurane for painful leg ulcers," PLOS ONE, Public Library of Science, vol. 16(9), pages 1-18, September.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:1:y:2017:i:1:d:10.1007_s41669-016-0009-9. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.